A large-scale, placebo-controlled clinical study shows a remarkable benefit from adding exenatide, a short-acting GLP-1 receptor agonist, to insulin glargine, on a background of metformin and/or pioglitazone, in patients with type 2 diabetes mellitus. Is this partnership here to stay?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The Wedding Bells Sound Really Good! iGlarLixi Fixed-Ratio Combination in the Treatment of Type 2 Diabetes: A Narrative Review
Advances in Therapy Open Access 16 June 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Buse, J. B. et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: A randomized, controlled trial. Ann. Intern. Med. 154, 103–112 (2010).
Drucker, D. J. & Nauck, M. A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696–1705 (2006).
Holman, R. R. et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N. Engl. J. Med. 361, 1736–1747 (2009).
Cusi, K., Cunningham, G. R. & Comstock, J. P. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. Diabetes Care 18, 843–851 (1995).
Linn, T. et al. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 93, 3839–3846 (2008).
Linnebjerg, H. et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul. Pept. 151, 123–129 (2008).
Buse, J. B. et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374, 39–47 (2009).
Arnolds, S. et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 33, 1509–1515 (2010).
Nathan, D. M. et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52, 17–30 (2009).
Russell-Jones, D. et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52, 2046–2055 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M. A. Nauck has been member on advisory boards or has consulted with AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., GlaxoSmithKline, Hoffman—La Roche, Menarini/Berlin Chemie, Merck, Sharp & Dohme, NovoNordisk, Versatis. He has received grant support from Eli Lilly & Co., Menarini/Berlin-Chemie, Merck, Sharp & Dohme, Novartis Pharma, and Ypsomed. He has also served on the speakers' bureau of AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Hoffman—La Roche, Menarini/Berlin Chemie, Merck, Sharp & Dohme, and NovoNordisk.
J. J. Meier has been member on advisory boards or has consulted with AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., GlaxoSmithKline, Merck, Sharp & Dohme, Sanofi-Aventis and NovoNordisk. He has received grant support from Eli Lilly & Co., Merck, Sharp & Dohme, Novartis Pharma, and Sanofi-Aventis. He has also served on the speakers' bureau of AstraZeneca, Eli Lilly & Co., Novartis, Merck, Sharp & Dohme, Sanofi-Aventis and NovoNordisk.
Rights and permissions
About this article
Cite this article
Nauck, M., Meier, J. GLP-1 analogues and insulin: sound the wedding bells?. Nat Rev Endocrinol 7, 193–195 (2011). https://doi.org/10.1038/nrendo.2011.30
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2011.30
This article is cited by
-
The Wedding Bells Sound Really Good! iGlarLixi Fixed-Ratio Combination in the Treatment of Type 2 Diabetes: A Narrative Review
Advances in Therapy (2023)
-
Warum ist eine Kombination von Basalinsulin mit einem GLP-1-Rezeptoragonisten bei vielen Patienten mit Typ-2-Diabetes sinnvoll?
MMW - Fortschritte der Medizin (2017)
-
Inkretinbasierte Therapien
Der Diabetologe (2013)
-
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Nature Reviews Endocrinology (2012)